drugset / Trial / NCT02044874

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874

Phase 2 Completed 603 enrolled Arena Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.

Timeline

Start
2014-03
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorcaserin Small molecule 10 mg Oral

Indications

No indication recorded.